Depo-Provera MDL update: what the June rulings mean for meningioma claims
If you used Depo-Provera and later heard the word “meningioma,” the court updates can feel like they are written for everyone except the person actually living with the diagnosis. Here is the plain-English version of where the federal Depo-Provera litigation stands in mid-July 2026, and what records matter most right now.
The federal case is active in Florida
The Depo-Provera meningioma cases are centralized in MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers. The court’s MDL page says the Judicial Panel on Multidistrict Litigation moved the cases there on February 7, 2025.
The shared allegation is direct: people claim injectable Depo-Provera, or generic depot medroxyprogesterone acetate, can cause users to develop one or more meningiomas. The defendants deny that the medication is unsafe. That dispute is exactly why the MDL matters. One judge can manage discovery, expert challenges, and common legal issues instead of hundreds or thousands of courts doing the same work separately.
The MDL has grown quickly. Public lawsuit trackers were reporting thousands of pending federal cases by summer 2026, and one July 2026 litigation update placed the federal MDL count at 5,830 pending lawsuits. State court cases may not be included in that number.
What changed in June
The court’s public order list shows a June 23, 2026 entry called Pretrial Order No. 30A. The order applies rulings on preemption and Rule 702 expert issues to individual actions.
That matters because these two fights often shape the whole case:
- Preemption asks whether federal drug-label law blocks certain warning claims.
- Rule 702, often called a Daubert challenge, asks whether expert opinions are reliable enough for trial.
For families, the practical takeaway is simpler: the litigation is not just sitting on a docket. The court is working through the gatekeeping questions that decide what evidence can be used and how individual claims move forward.
Some attorney litigation updates also reported that June deadlines connected to expert hearings or early trial preparation shifted while the parties worked through case-management and resolution issues. I would treat any “settlement” headline carefully unless and until there is a final, court-approved program with written eligibility rules. As of this writing, people should not assume a payment amount, a deadline, or guaranteed eligibility based only on a blog headline.
The science people keep talking about
The study most people are citing is a 2024 French national case-control study published in The BMJ and indexed on PubMed. Researchers looked at women who had surgery for intracranial meningioma in France and compared them with matched controls.
For injectable medroxyprogesterone acetate, the study reported an odds ratio of 5.55, with a 95% confidence interval from 2.27 to 13.56. The authors wrote that the excess risk was driven by prolonged use, meaning use for at least one year.
That does not prove every individual case. It does explain why long-term Depo-Provera exposure plus a later meningioma diagnosis is getting serious attention in court.
What claimants should gather now
If you are trying to understand whether your history fits the cases being investigated, start with documents, not memory. The most useful records usually include:
- pharmacy records showing Depo-Provera or generic medroxyprogesterone acetate injections;
- OB-GYN or clinic records with injection dates;
- imaging reports, such as MRI or CT scans, showing a meningioma;
- neurosurgery, radiation, oncology, or neurology notes;
- pathology reports, if surgery happened;
- a short timeline of symptoms, diagnosis, treatment, and follow-up care.
Do not panic if you do not have every record today. Many clinics and pharmacies can produce older records, but it can take time. The sooner you request them, the better.
Common questions we are hearing
Does every brain tumor qualify?
No. These cases focus on meningioma, not every type of brain tumor. The exact medical diagnosis matters.
Does one shot qualify?
The strongest science discussed in the litigation points to prolonged use. That does not mean a shorter history should be ignored, but injection history is one of the first things lawyers will review.
Is there already a guaranteed settlement?
No guaranteed result should be promised. The MDL is moving, and there are reports of active resolution discussions, but a person’s claim still depends on exposure records, diagnosis, timing, medical proof, and legal deadlines.
Should I stop or change medication because of a lawsuit?
Medical decisions should be made with a licensed healthcare professional. If you are currently using Depo-Provera or any contraceptive medication, talk with your doctor about your risk factors and alternatives.
Why timing matters
Statutes of limitation are different from state to state. Some deadlines may turn on the date of diagnosis. Others may involve when a person reasonably connected the diagnosis to the drug. Waiting can make records harder to find and can create legal problems even for a serious injury.
If you used Depo-Provera for a long period and were later diagnosed with a meningioma, the next step is usually a record review. A careful review can separate a possible claim from a case that does not fit the current litigation.
This article is attorney advertising and is for general information only. It is not medical advice and does not create an attorney-client relationship. Past results and litigation updates do not guarantee any future outcome.
Sources checked
- U.S. District Court for the Northern District of Florida, Depo-Provera Products Liability Litigation, MDL No. 3140.
- Northern District of Florida order list for MDL No. 3140, including the June 23, 2026 Pretrial Order No. 30A entry.
- PubMed abstract for the 2024 BMJ French national case-control study on progestogens and intracranial meningioma.
- Lawsuit Information Center July 2026 Depo-Provera litigation update for current public case-count and litigation-status reporting.
